OrthoLogic Corp.'s initiation of dosing for its AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring brings good news to people who look for cosmetic solutions to hide such scars. Dermal scars that often result from surgical procedures can cause psychological trauma in patients. At present there are no prescription drugs that treat this problem.

Highlights of the study
a. This study is a randomized, placebo controlled, dose-escalation, single center study.
b. Its objective is to review the safety and tolerability of increasing dosage of AZX100.
c. All the 30 volunteers are healthy adult males.
d. They will be enrolled at an experienced inpatient Phase 1 study clinic.
e. The idea is to develop a safe and effective medication for the market.

Highlights of AZX100
a. This is basically a synthetic pre-clinical 24-amino acid peptide.
b. It induces muscle and fibrosis relaxation.
c. It is currently being evaluated for the treatment of pulmonary disease, prevention of hypertrophic and keloid scarring and intimal hyperplasia.
d. It stimulates the cells that causes angiogenesis, leads to revascularization and repairs dermal and musculoskeletal tissues.
e. It is being studied in disorders that involve vascular endothelial dysfunction.
f. Multiple pre-clinical and clinical trials have proved its efficacy.